

12 July 2023

ASX Announcement

Firebrick Update on Phase 2 Trial Results

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) advises the market that the results of its Phase 2 trial of Nasodine® Nasal Spray (“Nasodine”) will be available by the end of July.

This Phase 2 COVID-19 shedding study was conducted in South Africa and results were previously expected in early July (see ASX announcement 20 June 2023). However, due to unavailability of the Company’s statistician due to travel until after 21 July, the headline results can now be expected in the last week of July.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded with the mission to commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also has a third patent family covering the Nasodine formulation, which has been granted in Australia. Firebrick is currently completing a second Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results will also be important for securing regulatory approvals and partnerships in major markets outside Australia.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com